Anticonvulsant-induced dyskinesia

Bibliography

• HARRISON MB, LYONS GR, LANDOW ER Phenytoin and dyskinesias: a report of two cases and review of the literature. Mov. Disord. (1993) 8(1):19–27.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of phenytoin-associatedmovement disorders.
   Google Scholar
• RASMUSSEN S, KRISTENSEN M: Choreoathetosis during phenytoin treatment. Acta Med. Scand. (1977) 201(3):239–241.
   PubMed Web of Science ®Google Scholar
• •Useful review of risk factors associated with phenytoin-induced dyskinesias.
   Google Scholar
• WIZNITZER M, YOUNKIN D: Phenobarbital-induced dyskinesia in a neurologically-impaired child. Neurology (1984) 34(12):1600–1601.
   PubMed Web of Science ®Google Scholar
• •Case report stressing similarities with phenytoin-induced dyskinesia.
   Google Scholar
• YOSHIDA M, YAMADA S, OZAKI Y, NAKANISHI T: Phenytoin-induced orofacial dyskinesia. A case report. J. NeuroL (1985) 231(6):340–342.
   Google Scholar
• KOUKKARI MW, VANEFSKY MA, STEINBERG GK, HAHN JS: Phenytoin-related chorea in children with deep hemispheric vascular malformations. J. Child NeuroL (1996) 11(6):490–491.
   PubMed Web of Science ®Google Scholar
• MONTENEGRO MA, SCOTONI AE, CENDES F: Dyskinesia induced by phenytoin. Arq. Neuropsiquiatr. (1999) 57(2B):356–360.
   Google Scholar
• •Recent review of phenytoin-induced movement disorders.
   Google Scholar
• ZAATREH M, TENNISON M, D'CRUZ O, BEACH RL: Anticonvulsants-induced chorea: a role for pharmacodynamic drug interaction? Seizure (2001) 10(8):596–599.
   PubMed Web of Science ®Google Scholar
• •Report of three patients with a pathophysiolgical explanation for AID.
   Google Scholar
• LUHDORF K, LUND M: Phenytoin-induced hyperkinesia. Epilepsia (1977) 18:409–415.
   PubMed Web of Science ®Google Scholar
• CHALHUB EG, DE VIVO DC: Phenytoin-induced choreoathetosis. J. Pediatr. (1976) 89:153–165.
   PubMed Web of Science ®Google Scholar
• HOWRIE DL, CRUMRINE PK : Phenytoin-induced movement disorder associated with intravenous administration for status epilepticus. Clin. Pediatr. (1985) 24(8):467–469.
   PubMed Web of Science ®Google Scholar
• •An explanation of the higher risk of AID with intravenous drug administration.
   Google Scholar
• CHAUDHARY N, RAVAT SH, SHAH PU: Phenytoin-induced dyskinesia. Indian Pediatr. (1998) 35(3):274–276.
   PubMedGoogle Scholar
• KURLAN R, KERSUN J, BEHR J et al.: Carbamazepine-induced tics. Clin. Neurophormacd. (1989) 12(4):298–302.
   PubMed Web of Science ®Google Scholar
• LOMBROSO CT: Lamotrigine-induced tourettism. Neurology (1999) 52:1191–1194.
   PubMed Web of Science ®Google Scholar
• SOTERO DE MENEZES MA, RHO JM, MURPHY P, CHEYETTE S: Lamotrigine-induced tic disorder: report of five pediatric cases. Epilepsia (2000) 41(7):862–867.
   PubMed Web of Science ®Google Scholar
• ••Tics as a complication of lamotrigine:clinical features and prognosis.
   Google Scholar
• BURD L, KERBESHIAN J, FISHER W, GASCON G: Anticonvulsant medications: an iatrogenic cause of tic disorders. Can. J. Psychiatry (1986) 31(5):419–423.
   PubMed Web of Science ®Google Scholar
• NAUSIEDA PA, KOLLER WC, KLAWANS HL, WEINER WJ: Phenytoin and choreic movements. N EngL J. Med. (1978) 11(2901093–1094.
   Google Scholar
• LIGHTMAN SL: Phenobarbital dyskinesia. Postgrad. Med. J. (1978) 54(628):114–115.
   PubMed Web of Science ®Google Scholar
• CHUDNOW RS, DEWEY RB, LAWSON CR: Choreoathetosis as a side effect of gabapentin therapy in severely neurologically impaired patients. Arch. NeuroL (1997) 54(7):910–912.
   PubMed Web of Science ®Google Scholar
• •Considered a very safe drug, gabapentin can still cause dyskinesia.
   Google Scholar
• NORTON JW, QUARLES E: Gabapentin-related dyskinesia. J. Clin. PsychopharmacoL (2001) 21 (6) :623–624.
   PubMed Web of Science ®Google Scholar
• SCHWARTZMAN MJ, LEPPIK IE: Carbamazepine-induced dyskinesia and ophthalmoplegia. Cleve. Clin. J. Med. (1990) 57(0367–372.
   PubMed Web of Science ®Google Scholar
• MURPHY MJ, GOLDSTEIN MN: Diphenylhydantoin-induced asterixis. A clinical study. JAMA (1974) 29(229):538–540.
   Google Scholar
• CHI WM, CHUA KS, KONG KEI: Phenytoin-induced asterixis - uncommon or under-diagnosed? Brain Inj. (2000) 14(9):847–850.
   Google Scholar
• •Stressing the fact that AID is probably underdiagnosed.
   Google Scholar
• SHULMAN LM, SINGER C, WEINER WJ: Phenytoin-induced focal chorea. Mov. Disord (1996) 11 (1): 111–114.
   PubMed Web of Science ®Google Scholar
• •Focal dyskinesia, a sign for focal pathology?
   Google Scholar
• DUARTE J, SEMPERE AP, CABEZAS MC, MARCOS J, CLAVERIA LE: Postural myoclonus induced by phenytoin. Clin. NeuropharmacoL (1996) 19(0:536–538.
   PubMedGoogle Scholar
• SECHI GP, PIRAS MR, ROSATI G et al.: Phenobarbital-induced buccolingual dyskinesia in oral apraxia. Eur. Neurol. (1988) 28(3):139–141.
   PubMed Web of Science ®Google Scholar
• PETERS HA: Anticonvulsant drug intolerance. Neurology (1962) 12:299.
   Google Scholar
• •The first description of AID.
   Google Scholar
• FILLOUX F, THOMPSON JA: Transient chorea induced by phenytoin. J. Pediatr. (1987) 110:639–641.
   PubMed Web of Science ®Google Scholar
• TURKDOGAN D, ONAT F, TURE U, PAMIR N: Phenytoin toxicity with mandibular tremor secondary to intravenous administration. Intl. Clin. PharmacoL Ther. (2002) 40(1):18–19.
   PubMed Web of Science ®Google Scholar
• MOSS W, ojuKwu C, CHIRIBOGA CA: Phenytoin-induced movement disorder. Unilateral presentation in a child and response to diphenhydramine. Clin. Pediatr. (1994) 33(10):634–638.
   Google Scholar
• GONI M, JIMENEZ M, FEIJO0 M: Parkinsonism induced by phenytoin. Clin. Neurophormacd. (1985) 8(4):383–384.
   PubMed Web of Science ®Google Scholar
• PRENSKY AL, DEVIVO DC, PALKES H: Severe bradykinesia as a manifestation of toxicity to antiepileptic medications. J. Pediatr. (1971) 78(4):700–704.
   PubMed Web of Science ®Google Scholar
• HOLTMANN M, KORN-MERKER E, BOENIGK HE: Carbamazepine-induced combined phonic and motor tic in a boy with Down's syndrome. Epileptic Disord (2000) 2(0:39–40.
   PubMedGoogle Scholar
• AGUGLIA U, ZAPPIA M, QUATERONE k Carbamazepine-induced nonepileptic myoclonus in a child with benign epilepsy. Epilepsia (1987) 28(5):515–518.
   PubMed Web of Science ®Google Scholar
• AMBROSETTO G, RIVA R, BARUZZI A: Hyperammonemia in asterixis induced by carbamazepine: two case reports. Acta NeuroL Scand. (1984) 69 (3) :186–189.
   PubMed Web of Science ®Google Scholar
• •Metabolic derangement as a risk for AID.
   Google Scholar
• RITTMANNSBERGER H, LEBLHUBER F: Asterixis induced by carbamazepine therapy. Biol. Psychiatry (1992) 32(4):364–368.
   PubMed Web of Science ®Google Scholar
• GIGLI GL, SCALISE A, SILVESTRI G et al.: Clinical case report: multiple idiosyncratic adverse effects of antiepileptic drugs in trisomy 9p. Int. J. Neurosci. (1996) 87(3-4):181–189.
   PubMed Web of Science ®Google Scholar
• CROSLEY CJ, SWENDER PT: Dystonia associated with carbamazepine
   Google Scholar
• •• administration: experience in brain-damaged children. Pediatrics (1979) 63(4):612–615.
   Google Scholar
• STRYJER R, STROUS RD, BAR F, ULMAN AM, RABEY JM: Segmental dystonia as the sole manifestation of carbamazepine toxicity. Gen. Hosp. Psychiatry (2002) 24(2):114–115.
   PubMed Web of Science ®Google Scholar
• BIMPONG-BUTA K, FROESCHER W: Carbamazepine-induced choreoathetoid dyskinesias. J. Neurol. Neurosurg. Psychiatry (1982) 45:560.
   PubMed Web of Science ®Google Scholar
• JOYCE RP, GUNDERSON CH: Carbamazepine-induced orofacial dyskinesia. Neurology (1980) 30(12):1333–1334.
   PubMed Web of Science ®Google Scholar
• JACOME D: Movement disorder induced by carbamazepine. Neurology (1981) 31(01059–1060.
   PubMed Web of Science ®Google Scholar
• WEAVER DF, CAMFIELD P, FRASER A: Massive carbamazepine overdose: clinical and pharmacologic observations in five episodes. Neurology (1988) 38(5):755–759.
   PubMed Web of Science ®Google Scholar
• GUNAL DI, GULERYUZ M, BINGOL CA Reversible valproate-induced choreiform movements. Seizure (2002) 11(3):205–206.
   PubMed Web of Science ®Google Scholar
• LANCMAN ME, ASCONAPE JJ, PENRY JK: Choreiform movements associated with the use of valproate. Arch. Neurol. (1994) 51:702–704.
   PubMed Web of Science ®Google Scholar
• KLAWANS HL, CARVEY PM, TANNER CM: Drug induced myoclonus. Adv. Neurol. (1986) 43:251–261.
   PubMedGoogle Scholar
• ONOFRJ M, THOMAS A, PACT C: Reversible parkinsonism induced by prolonged treatment with valproate. J. Neurol. (1998) 245(12):794–796.
   PubMed Web of Science ®Google Scholar
• ARMON C, SHIN C, MILLER P et al.: Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology (1996) 47(3):626–635.
   PubMed Web of Science ®Google Scholar
• •Description of the variable degree of parkinsonism in 36 patients with chronic valproate therapy.
   Google Scholar
• SASSO E, DELSOLDATO S, NEGROTTI A, MANCIA D: Reversible valproate-induced extrapyramidal disorders. Epilepsia (1994) 35(2):391–393
   PubMed Web of Science ®Google Scholar
• ALVAREZ-GOMEZ MJ, VAAMONDE J, NARBONA J et al.: Parkinsonian syndrome in childhood after sodium valproate administration. Clin. Neuropharmacol. (1993) 16(5):451–455.
   PubMed Web of Science ®Google Scholar
• EHYAI A, KILROY AW, FENICHEL GM: Dyskinesia and akathisia induced by ethosuximide. Am. J. Dis. Child. (1978) 132(5):527–528.
   PubMedGoogle Scholar
• KIRSCHBERG GJ: Dyskinesia: an unusual reaction to ethosuximide. Arch. Neurol. (1975) 32:137–138.
   PubMed Web of Science ®Google Scholar
• DOOLEY J, CAMFIELD P, BUCKLEY D, GORDON K, WIRRELL E, CAMFIELD C: Methsuximide-induced movement disorder. Pediatrics (1991) 88(6): 1291–1292.
   PubMed Web of Science ®Google Scholar
• KERRICK JM, KELLEY BJ, MAISTER BH, GRAVES NM, LEPPIK IE: Involuntary movement disorders associated with felbamate. Neurology (1995) 45 (1): 185–187.
   PubMed Web of Science ®Google Scholar
• REEVES AL, SO EL, SHARBROUGH FW, KRAHN LE: Movement disorders associated with the use of gabapentin. Epilepsia (1996) 37(10):988–990.
   PubMed Web of Science ®Google Scholar
• BUETEFISCH CM, GUTIERREZ A, GUTMANN L: Choreoathetotic movements: a possible side effect of gabapentin. Neurology (1996) 46(3):851–852.
   PubMed Web of Science ®Google Scholar
• JACOB PC, CHAND RP, OMEIMA EL-S: Asterixis induced by gabapentin. Clin. Neuropharmacol. (2000) 23(1):53.
   PubMed Web of Science ®Google Scholar
• HUPPERTZ HJ, FEUERSTEIN TJ, SCHULZE-BONHAGE A: Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia (2001) 42(6):790–792.
   PubMed Web of Science ®Google Scholar
• •Myoclonus in an epileptic patient is not always epilepsy.
   Google Scholar
• JONGSMA MJ, LAAN LA, VAN EMDE BOAS W, MEINARDI H: Reversible motor disturbances induced by vigabatrin. Lancet (1991) 338(8771):893.
   PubMed Web of Science ®Google Scholar
• WOLANCZYK T, GRABOWSKA-GRZYB A: Transient dystonias in three patients treated with tiagabine. Epilepsia (2001) 42(7):944–946.
   PubMed Web of Science ®Google Scholar
• FROST MD, RITTER FJ, HOSKIN C, MIMS J, ESPO-LILLO J: Movement disorder associated with lamotrigine treatment in children and adolescents. Epilepsia (1996) 37:112. Abstract.
   Google Scholar
• VERMA A, MILLER P, CARWILE ST, HUSAIN AM, RADTKE RA: Lamotrigine-induced blepharospasm. Pharmacotherapy (1999) 19(7):877–880.
   PubMed Web of Science ®Google Scholar
• ROSENBAUM AH, DE LA FUENTE JR: Benzodiazepines and tardive dyskinesia. Lancet (1979) 27:200–201.
   Google Scholar
• STOLAREK IH, FORD MJ: Acute dystonia induced by midazolam and abolished by flumazenil. Br. Med. J. (1990) 300:614–615.
   PubMed Web of Science ®Google Scholar
• DULAC O, BONUCCELLI U: Seizures and movement disorders precipitated by drugs. In: Epilepsy and movement disorders. Guerrini R, Aicardi J, Andermann F, Hallett M (Eds), Cambridge University Press (2002).
   Google Scholar
• •Excellent recent comprehensive review.
   Google Scholar
• REUTENS DC, DUNCAN JS, PATSALOS PN: Disabling tremor after lamotrigine with sodium valproate. Lancet (1993) 17(342):185–186.
   Google Scholar
• EDWARDS KR Felbamate and tremor. Neurology (1995) 45(101951.
   Google Scholar
• PERUCCA E: Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs (2002) 16(10695–714.
   Google Scholar
• WATTS RL, KOLLER WC: Movement disorders: Neurologic principles and practice. Watts RL, Koller KC (Eds), McGraw-Hill Professional, New York (1997).
   Google Scholar
• SETHI KD, HITRI A, DIAMOND BI: Phenytoin potentiation of neuroleptic-induced dyskinesias. Mov. Disord. (1990) 5(4):325–327.
   PubMed Web of Science ®Google Scholar
• ••Excellent study with some pathophysiolgical implications of AID.
   Google Scholar
• JIMENEZ-JIMENEZ FJ, GARCIA-RUIZ PJ, MOLINA JA: Drug-induced movement disorders. Drug Saf (1997) 16(3):180–204.
   PubMed Web of Science ®Google Scholar
• BLAKELEY J, JANKOVIC J: Secondary paroxysmal dyskinesias. Mov. Disord. (2002) 17(4):726–734.
   PubMed Web of Science ®Google Scholar
• DHANARAJ M, RADHAKRISHNAN AR, SRINIVAS K, SAYEED ZA: Sodium valproate in Sydenham's chorea. Neurology (1985) 35(1):114–115.
   PubMed Web of Science ®Google Scholar
• HARDOY MC, HARDOY MJ, CARTA MG, CABRAS PL: Gabapentin as a promising treatment for antipsychotic-induced movement disorders in schizoaffective and bipolar patients. J. Affect. Disord (1999) 54(3):315–317.
   PubMed Web of Science ®Google Scholar
• GENEL F, ARSLANOGLU S, URAN N, SAYLAN B: Sydenham's chorea: clinical findings and comparison of the efficacies of sodium valproate and carbamazepine regimens. Brain Dev. (2002) 24(2):73–76.
   PubMed Web of Science ®Google Scholar
• NUTT GJ: Levodopa-induced dyskinesia: review, observations and speculations. Neurology (1990) 40:340–345.
   PubMed Web of Science ®Google Scholar
• WALDMEIER PC: Is there a common denominator for the antimanic effect of lithium and anticonvulsants? Pharmacopsychiatry (1987) 20:37-47. 392
   Google Scholar
• CHADWICK D, REYNOLDS EH, MARSDEN CD: Anticonvulsant-induced dyskinesias: a comparison with dyskinesias induced by neuroleptics. J. Neurol Neurosurg-. Psychiatry (1976) 39(12):1210–1218.
   PubMed Web of Science ®Google Scholar
• •Pathophysiolgy of AID.
   Google Scholar
• CALABRESI P, GIACOMINI P, CENTONZE D, BERNARDI G: Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann. Neurol (2000) 47(4 Suppl. 1):560–568. Discussion S68–S69.
   Google Scholar
• LEACH MJ, MARDEN CM, MILLER AA:Pharmacological studies on lamotrigine,a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia (1986) 27:490–497.
   PubMed Web of Science ®Google Scholar
• MELDRUM BS: Excitatory amino acid transmitters in epilepsy. Epi/epsia (1991) 32:S1–S3.
   PubMed Web of Science ®Google Scholar
• STARR MS, STARR BS, KAUR S: Stimulation of basal and L-DOPA-induced motor activity by glutamate antagonists in animal models of Parkinson's disease. Neurosci. Biobehav. Rev. (1997) 21:437–446.
   PubMed Web of Science ®Google Scholar
• SHINOTOH H, VINGERHOETS FJ, LEE CS et al.: Lamotrigine trail in idiopathic parkinsonism: a double-blind, placebo-controlled, crossover study. Neurology (1997) 48:1282–1285.
   PubMed Web of Science ®Google Scholar
• RICHTER A, LOSCHMANN PA, LOSCHER W: The novel antiepileptic drug, lamotrigine, exerts prodystonic effects in a mutant hamster model of generalized dystonia. Eur. J. Pharmacol (1994) 3(264):345–351.
   Google Scholar